— Know what they know.
Not Investment Advice

APUS AMEX

Apimeds Pharmaceuticals US, Inc
1W: -55.6% 1M: +22.4% 3M: -62.6% YTD: -80.7% 1Y: -81.2%
$3.22
-0.88 (-21.46%)
 
Weekly Expected Move ±68.6%
$-1 $1 $3 $5 $8
AMEX · Healthcare · Biotechnology · Tech Score Neutral · Power 48 · $4.9M mcap · 563192 float · 267.23% daily turnover · Short 44% of daily vol

Balance Sheet Trends

Total Assets
$13K -96.9% ▼
3Y CAGR: -57.7%
Total Liabilities
$1M +251.4% ▲
3Y CAGR: +49.5%
Shareholders Equity
-$1M -4361.3% ▼
Cash & Investments
$3K -99.2% ▼
3Y CAGR: -72.8%
Total Debt
$597K +123.6% ▲
3Y CAGR: +14.3%
Net Debt
$593K +513.3% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024
— Assets —
Cash$171K$6K$410K$3K
Short-Term Investments$0$0$0$0
Cash & ST Investments$171K$6K$410K$3K
Net Receivables$0$0$0$0
Inventory$0$0$0$0
Other Current Assets$0$0$12K$0
Total Current Assets$172K$6K$422K$13K
Property, Plant & Equip.$0$0$0$0
Goodwill & Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Other Non-Current Assets$0$0$0$0
Total Non-Current Assets$0$0$0$0
Total Assets$172K$6K$422K$13K
— Liabilities —
Accounts Payable$11K$37K$0$0
Short-Term Debt$0$260K$0$250K
Deferred Revenue$0$0$0$0
Other Current Liabilities$0$0$0$181K
Total Current Liabilities$11K$320K$123K$1M
Long-Term Debt$400K$400K$267K$347K
Other Non-Current Liab.$0$0$0$0
Total Non-Current Liabilities$400K$400K$267K$347K
Total Liabilities$411K$720K$390K$1M
— Equity —
Common Stock$100K$100K$206K$79K
Retained Earnings-$2M-$2M-$3M-$4M
Accumulated OCI$0$0$0$0
Total Stockholders Equity-$238K-$714K$32K-$1M
Total Liabilities & Equity$172K$6K$422K$13K
— Key Metrics —
Total Debt$400K$660K$267K$597K
Net Debt$229K$654K-$144K$593K
Total Investments$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms